AstraZeneca - interlocutory injunction denied

ASTRAZENECA - INTERLOCUTORY INJUNCTION TO PREVENT MARKETING OF A GENERIC OMEPRAZOLE PRODUCT IN GERMANY DENIED AstraZeneca today announced that its request for an interlocutory injunction in Germany to prevent Azupharma GmbH from marketing a generic omeprazole version has been denied by the Appeal Court in Frankfurt. Omeprazole is the ® substance used in Losec . AstraZeneca has filed requests in Germany for preliminary injunctions against eight companies, has filed six main actions and is currently defending its patent rights in seven other patent cases related to omeprazole. In August 1999, AstraZeneca was granted an interlocutory injunction to prevent Ratiopharm GmbH and Merckle GmbH selling a generic version of omeprazole. The substance patent for omeprazole began expiring in the first countries in 1999. In most countries, AstraZeneca has been granted Patent Term Extensions or Supplementary Protection Certificates (SPCs). This extended coverage for the substance expires in the USA in 2001, in most European countries in 2002- 2004, and in Japan in 2004. The product is also protected by patents directed to formulations, uses, intermediates and processes. Further Enquiries: Media: Staffan Ternby, tel: +44 Steve Brown, tel +44 8 553 261 07 171 304 5033 Lucy Williams, tel +44 171 304 5034 Investor Relations: Staffan Ternby, tel: +44 Michael Olsson, tel +46 8 553 261 07 553 259 52 Elizabeth Sutton, tel +44 Jörgen Winroth, tel +1 171 304 5101 609 896 4148 Ed Seage, tel +1 302 886 4065 ------------------------------------------------------------ Please visit for further information The following files are available for download:

About Us

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit: